NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
This publication is provided for historical reference only and the information may be out of date.
Overactive bladder syndrome (OAB) is defined by the International Continence Society (ICS) as a medical condition referring to the urinary symptoms of frequency and urgency, with or without urge incontinence, when appearing in the absence of local pathological factors. Nocturia is also commonly present. The purpose of this review is to compare the efficacy, effectiveness, and adverse effects of the pharmacological treatments for OAB. Pharmacological treatment includes darifenacin, flavoxate hydrochloride, hyoscyamine, oxybutynin chloride, tolterodine tartrate, trospium chloride, scopolamine transdermal, and solifenacin succinate.
Contents
- Introduction
- Methods
- Results
- Overview
- Systematic Reviews
- Key Question 1. For adult patients with urinary urge incontinence/overactive bladder, do anticholinergic OAB drugs differ in effectiveness?
- Quality of life
- Abstracts: Assessment of Publication Bias
- Key Question 2. For adult patients with urinary urge incontinence/overactive bladder, do anticholinergic OAB drugs differ in safety or adverse effects?
- CNS Adverse Events
- Withdrawal Due to Adverse Events
- Drug Interactions
- Abstracts: Assessment of Publication Bias
- Key Question 3. Are there subgroups of patients based on demographics (age, racial groups, gender), other medications, or co-morbidities for which one anticholinergic incontinence drug is more effective or associated with fewer adverse effects?
- Summary and Discussion
- Flavoxate
- Scopolamine
- Hyoscyamine
- Evidence of Comparative Efficacy: Oxybutynin versus Tolterodine
- Evidence of Comparative Efficacy: Oxybutynin versus Trospium
- Evidence of Comparative Efficacy: Tolterodine versus Solifenacin
- Evidence of Comparative Adverse Events: Oxybutynin versus Tolterodine
- Evidence of Comparative Adverse Events: Oxybutynin versus Trospium
- Evidence of Comparative Adverse Events: Darifenacin versus Oxybutynin
- Evidence of Comparative Adverse Events: Solifenacin versus Tolterodine
- Evidence of Comparative Efficacy or Adverse Events in Subgroup: Oxybutynin versus Tolterodine or Trospium
- References
- Appendixes
- Evidence Tables
The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports.
- Review Drug Class Review: Agents for Overactive Bladder: Final Report Update 4[ 2009]Review Drug Class Review: Agents for Overactive Bladder: Final Report Update 4McDonagh MS, Selover D, Santa J, Thakurta S. 2009 Mar
- Agents for treatment of overactive bladder: a therapeutic class review.[Proc (Bayl Univ Med Cent). 2007]Agents for treatment of overactive bladder: a therapeutic class review.Hesch K. Proc (Bayl Univ Med Cent). 2007 Jul; 20(3):307-14.
- The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.[BJU Int. 2010]The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.Cardozo L, Thorpe A, Warner J, Sidhu M. BJU Int. 2010 Aug; 106(4):506-14. Epub 2010 Feb 3.
- Treatments for overactive bladder: focus on pharmacotherapy.[J Obstet Gynaecol Can. 2012]Treatments for overactive bladder: focus on pharmacotherapy.Geoffrion R, UROGYNAECOLOGY COMMITTEE. J Obstet Gynaecol Can. 2012 Nov; 34(11):1092-1101.
- Review Urgency in overactive bladder: translating experimental data into clinical practice.[Drugs Today (Barc). 2008]Review Urgency in overactive bladder: translating experimental data into clinical practice.Wyndaele JJ, De Wachter S. Drugs Today (Barc). 2008 May; 44(5):381-9.
- Drug Class Review on Agents for Overactive BladderDrug Class Review on Agents for Overactive Bladder
Your browsing activity is empty.
Activity recording is turned off.
See more...